Appearance of new vemurafenib-associated melanocytic nevi on normal-appearing skin: Case series and a review of changing or new pigmented lesions in patients with metastatic malignant melanoma after initiating treatment with vemurafenib

Journal of Clinical and Aesthetic Dermatology

Volumn 6, Issue 5, 2013, Pages 27-37

  Cohen, Philip R ^a   Bedikian, Agop Y ^b   Kim, Kevin B ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLINDAMYCIN; DABRAFENIB; INTERFERON; IPILIMUMAB; SORAFENIB; TEMOZOLOMIDE; TRAMETINIB; VEMURAFENIB;

ALOPECIA; APOPTOSIS; ARTHRALGIA; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER STAGING; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; CONFOCAL MICROSCOPY; CRYOTHERAPY; DARIER DISEASE; DRUG MEGADOSE; DRY SKIN; DYSPLASTIC NEVUS; EPILUMINESCENCE MICROSCOPY; HISTOPATHOLOGY; HUMAN; KERATOACANTHOMA; KERATOSIS; LYMPH NODE DISSECTION; MELANOCYTIC NEVUS; MELANOMA; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PLEURA EFFUSION; PROXIMAL INTERPHALANGEAL JOINT; PRURITUS; PUNCH BIOPSY; RASH; REVIEW; SKIN DISEASE; SKIN MANIFESTATION; SOLAR RADIATION; SQUAMOUS CELL CARCINOMA; SUN EXPOSURE; SYSTEMATIC REVIEW; TRANSIENT ACANTHOLYTIC DERMATOSIS; UNSPECIFIED SIDE EFFECT; XEROSIS;

EID: 84878775551     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Jordan EJ, Kelly CM. Vemurafenib for the treatment of melanoma. Expert Opin Pharmacother. 2012; 13: 2533-2543.
2. Ravnan MC, Matalka MS. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. Clin Ther. 2012; 34: 1474-1486.
3. Fisher R, Larkin J. Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma. Cancer Management and Research. 2012; 4: 243-252.
4. Flaherty KT. BRAF inhibitors and melanoma. Cancer J. 2011; 17: 505-511.
5. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012; 366: 707-714.
6. Chapman PB, Hauschild A, Robert C, et al (BRIM-3 Study Group ). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364: 2507-2516.
7. Huang V, Hepper D, Anadkat M, Cornelius L. Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway. Arch Dermatol. 2102; 148: 628-633.
8. Boyd KP, Vincent B, Andea A, et al. Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma. J Am Acad Dermatol. 2012; 67: 1375-1379.
9. Zimmer L, Vaubel JV, Livingstone E, Schadendorf D. Side effects of systemic oncological therapies in dermatology. J Dtsch Dermatol Ges. 2012; 10: 475-486.
10. Drummer R, Rinderknecht J, Goldinger SM. Ultraviolet A and photosensitivity during vemurafenib therapy [letter]. N Engl J Med. 2012; 366: 480-481.
11. Harding JJ, Pulitzer M, Chapman PB. Vemurafenib sensitivity skin reaction after ipilimumab [letter]. N Engl J Med. 2012; 366: 866-868.
12. Sinha R, Edmonds K, Newton-Bishop JA, et al. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol. 2012; 167: 987-994.
13. Dalle S, Poulalhon N, Debarbieux S, Thomas L. Second primary melanomas under vemurafenib [letter[. Br J Dermatol. 2012 Oct 15 [Epub ahead of print].
14. Haenssle HA, Kraus SL, Brehmer F, et al. Dynamic changes in nevi of a patient with melanoma treated with vemurafenib. Importance of sequential dermatoscopy. Arch Dermatol. 2012; 148: 1183-1185.
15. Zimmer L, Hillen U, Livingstone E, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol. 2012; 30: 2375-2383.
16. Chu EY, Wanat KA, Miller CJ, et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol. 2012; 67: 1265-1267.
17. Gerami P, Sorrell J, Martini M. Dermatoscopic evolution of dysplastic nevi showing high-grade dysplasia in a metastatic melanoma patient on vemurafenib [letter]. J Am Acad Dermatol. 2012: 67: e275-e276.
18. Mattei PL, Alora-Palli MB, Kraft S, et al. Cutaneous effects of BRAF inhibitor therapy: a case series. Ann Oncol. 2013; 24: 530-537.
19. Debarbieux S, Dalle S, Depaepe L, et al. Secondary primary melanomas under BRAF blockers: study by reflectance confocal microscopy. Br J Dermatol. 2013 Jan 10 [Epub ahead of print].
20. Dalle S, Poulalhon N, Thomas L. Vemurafenib in melanoma with BRAF V600E mutation [letter]. N Engl J Med. 2011; 365: 1448-1449.
21. Chapman PB, Hauschild A, McArthur GA. Vemurafenib in melanoma with BRAF V600E mutation. The authors reply [letter]. N Engl J Med. 2011; 365: 1450.
22. Ma L, Dominguez AR, Collins GR, et al. Hidradenitis suppurativa, eruptive melanocytic nevi, and keratosis pilaris-like eruption in a patient treated with vemurafenib. Arch Dermatol. 2012; 148: 1428-1429.
23. Fearfield L, Newton-Bishop JA, Sinha R, et al. Second primary melanomas under vemurafenib - reply from the author [letter]. Br J Dermatol. 2012 Oct 15 [Epub ahead of print].
24. Mackie RM, English J, Aitchison TC, et al. The number and distribution of benign pigmented moles (melanocytic naevi) in a healthy British population. Br J Dermatol. 1985;113:167-174. (Pubitemid 15018548)
25. English DR, Armstrong BK. Melanocytic nevi in children. I. Anatomic sites and demographic and host factors. Am J Epidemiol. 1994;139:390-401. (Pubitemid 24081338)
26. Autier P, Boniol M, Severi G, et al for the Epidemiology, Prevention and Genetics Sub-group of the European Organization for Research and Treatment of Cancer (EORTC) Melanoma Co-operative Group (EPIMEL). The body site distribution of melanocytic naevi in 6-7 year old European children. Melanoma Res. 2001; 11: 123-131.
27. John JK, Smalley KSM. Identification of BRAF mutations in eruptive melanocytic nevi: new insights into melanomagenesis? Expert Rev Anticancer Ther. 2011; 11: 711-714.
28. Bovenschen HJ, Vermaat TH, de Hoop D, et al. Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biological. Br J Dermatol. 2006; 154: 880-884.
29. Reutter JC, Long EM, Morrell DS, et al. Eruptive postchemotherapy in situ melanomas and dysplastic nevi. Pediatr Dermatol. 2007;24:135-137. (Pubitemid 46495913)
30. Sekulic A, Colgan MB, Davis MDP, et al. Activating BRAF mutations in eruptive melanocytic naevi. Br J Dermatol. 2010; 163: 1095-1098.
31. Kong HH, Sibaud V, Turner MLC, et al. Sorafenib-induced eruptive melanocytic lesions. Arch Dermatol. 2008;144:820-822. (Pubitemid 351846901)
32. Bennani-Lahlou M, Mateus C, Escudier B, et al. Eruptive naevi associated with sorafenib treatment. Ann Dermatol Venereol. 2008; 135: 672-674.
33. Sibaud V. Cutaneous side effects of angiogenesis inhibitors in cancer patients. Oncologie. 2009; 11: 291-297.
34. Sibaud V, Delord J-P, Chevreau C, et al. Dermatologic adverse events of the new targeted anticancer therapies used in oncodermatology. Annales de Chirurgie Plastique Esthetique. 2012; 57: 106-113.
35. Robert C, Mateus C, Spatz A, et al. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol. 2009; 60: 299-305.
36. Arnault JP, Weschsler J, Escudier B, et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib [letter]. J Clin Oncol. 2009; 27: e59-e61.
37. Williams VL, Cohen PR, Stewart DJ. Sorafenib-induced premalignant and malignant skin lesions. Int J Dermatol. 2011; 50: 396-402.
38. Arnault JP, Mateus C, Escudier B, et al. Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res. 2011; 18: 263-272.